Hepatitis B Treatment Market Research Report - Forecast till 2032

Hepatitis B Treatment Market Research Report, By Type (Acute and Chronic), Treatment (Immune Modulator Drugs, Antiviral Drugs, Vaccine, and Surgery (Liver Transplant)), and Distribution Channel (Hospital & Retail Pharmacies)- Forecast till 2032

ID: MRFR/HC/6347-HCR | 110 Pages | Author: Kinjoll Dey | March 2024         

Hepatitis B Treatment Market Speak to Analyst Request a Free Sample

Hepatitis B Treatment Market Overview


The hepatitis b treatment market is expected to reach USD 129.40 Billion by 2032 at 4.5% CAGR during the forecast period 2023-2032.


The viral infection is caused by Hepatitis A, B or C virus which causes liver infection leading to liver damage. Hepatitis B virus can transmit in contact with infected blood, by consumption of contaminated water, and by using infected needles. Some of the major symptoms are weakness, jaundice, poor appetite, dark-coloured urine, skin itching, leg swelling, weight loss, drowsiness and others. The rise in concern for a better treatment for Hepatitis B is boosting the market at the global level.


The availability of hepatitis B treatment and the awareness of hepatitis B infections will significantly drive the market in the forecast period. The concern and reasonable treatment are the two growth factors that highly accelerate the market’s growth. The advancement in the development of new treatments and medications with a higher success rate will lead the market towards greater opportunities. The continuous development of drugs and vaccines for hepatitis B treatment is aiding the market. AIDS survivors with haemodialysis and immunosuppressants are propelling the market’s growth in the forecast period


Hepatitis B Treatment Market Segmentation


The hepatitis B treatment market is segmented on the basis of type, treatment, distribution channel, and region.


Based on type, the market is segmented into acute and chronic. On the basis of treatment, the hepatitis B treatment market is segmented into immune modulator drugs, antiviral drugs, vaccine, and surgery  (liver transplant). The immune modulator drugs are further sub-segmented into pegylated interferon and interferon alpha. The antiviral drugs are sub-segmented into tenofovir disoproxil, entecavir, telbivudine, lamivudine, and others. By distribution channel, the market is segmented into hospital & retail pharmacies and online pharmacies.


Based on region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.


Hepatitis B Treatment Market Key players


Some of the key players in the hepatitis B treatment market are Accord Healthcare Inc., Apotex Corp., Arbutus Biopharma, Arrowhead Pharma, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Par Pharmaceutical, Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, and Others.


Hepatitis B Treatment Regional Market Summary

Global Hepatitis B Treatment Market Share (%), by Region, 2017


Hepatitis B Treatment Market


Sources: Centers for Disease Control and Prevention, GOV.UK, Society of Cardiovascular Computed Tomography, Indian Brand Equity Foundation, Annual Reports, Press Release, White Paper, And Company Presentation


The Americas dominates the global market for hepatitis B treatment owing to the increasing bacterial infection, development in the clinical practices, and availability and access of best treatments for viral infection in this region.


Moreover, high healthcare expenditure within the Americas boosts the regional market. According to the National Vaccine Information Center, there were 3,370 acute cases of hepatitis B in the US in 2015. Following similar trends, Europe stood second in the global hepatitis B treatment market. On a regional basis, the European market is segmented into Western Europe and Eastern Europe. Europe is estimated to lead the market due to the presence of advanced medical facilities and rising viral infection among the population contributes to increasing the new cases of hepatitis B among the population. According to the World Health Organization data sheet, hepatitis B and C affects a large number of people in the European region. It also, stats that globally, 1.5 million people die every year because of hepatitis B virus. The increasing incidences of hepatitis B in Europe boost market growth.


Asia Pacific is estimated to be the fastest growing region for the hepatitis B treatment market in 2017. A rapidly growing medical diagnostic sector, growing prevalence of bacterial infection and a large number of patients suffering from HIV infection support market growth.


On the other hand, the Middle East and Africa hold the least share in the hepatitis B treatment market owing to stringent government policies, presence of poor economies, lack of awareness, and low healthcare expenditure within the region. Hepatitis B Treatment Market, by Type

  • Acute

  • Chronic


Hepatitis B Treatment Market, by Treatment

  • Immune Modulator Drugs

    • Pegylated Interferon

    • Interferon Alpha





  • Antiviral Drugs

    • Tenofovir disoproxil

    • Entecavir

    • Telbivudine

    • Lamivudine

    • Others





  • Vaccine

  • Surgery (Liver Transplant)


Hepatitis B Treatment Market, by Distribution Channel

  • Hospital & Retail Pharmacies

  • Online Pharmacies


Hepatitis B Treatment Market, by Key Players

  • Accord Healthcare Inc.

  • Apotex Corp.

  • Arbutus Biopharma

  • Arrowhead Pharma

  • Aurobindo Pharma Limited

  • Bristol-Myers Squibb Company

  • Gilead Sciences, Inc.

  • GlaxoSmithKline

  • Lupin Pharmaceuticals, Inc.

  • Merck & Co., Inc.

  • Par Pharmaceutical, Inc.

  • Teva Pharmaceuticals

  • Zydus Pharmaceuticals


Recent Development

In April 2022


Gilead Sciences, Inc. has declared that U.S. Food and Drug Administration (FDA) approved its new drug application (sNDA) for Veklury (remdesivir) for pediatric patients treatment older than 28 days, weighing 3 kg. Patients with COVID-19 or moderate COVID-19 are considered at high risk for progression hospitalization or death. This approval for sNDA follows Veklury non-hospitalized adult and adolescent patients treated at high risk of severe COVID-19.


In April 2022


Antios Therapeutics, Inc, a global clinical-stage biopharmaceutical company that has developed advanced therapies for the treatment of chronic hepatitis B virus. It has recently been announced that the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application Phosphoramidates for Hepatitis B Virus treatment. The compositions contain Antios' novel Active Site Polymerase Inhibitor Nucleotide), ATI-2173, along with other therapies and mechanisms.


Intended Audience

  • Pharmaceutical Companies

  • Biotechnological Institutes

  • Government and Private Laboratories

  • Research and Development (R&D) companies

  • Medical Research Laboratories

Report Scope:

Report Attribute/Metric Details
  Market Size   USD 129.40 Billion
  CAGR   4.5%
  Base Year   2021
  Forecast Period   2023-2032
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment, Distribution channel
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Accord Healthcare Inc., Apotex Corp., Arbutus Biopharma, Arrowhead Pharma, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Par Pharmaceutical, Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, and Others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers ·  Growing geriatric population ·  Increasing the prevalence of viral infection ·  Growing sexually transmitted diseases




Frequently Asked Questions (FAQ) :

Hepatitis B Treatment Market is expected to exhibit a strong 4.5% CAGR over the forecast period from 2023 to 2032.

The rising prevalence of hepatitis B is the major driver for the market.

The risk of side effects from hepatitis B therapeutics is the key restraint on the global hepatitis B treatment market.

The Americas dominates the global hepatitis B treatment market.

Leading players in the hepatitis B treatment market include Accord Healthcare, Bristol-Myers Squibb, Apotex, Aurobindo Pharma, and Merck, among others.

Key Questions Answered

  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players‚Äô financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample

Why Choose Market Research Future?

  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid